Create Free Account

By creating account you will get access to hot stocks & personalised emails

Zelira Therapeutics Ltd

Healthcare AU ZLD

0.62AUD
0.01(1.64%)

Last update at 2024-12-19T04:21:00Z

Day Range

0.620.69
LowHigh

52 Week Range

0.281.09
LowHigh

Fundamentals

  • Previous Close 0.61
  • Market Cap6.81M
  • Volume6916
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.54367M
  • Revenue TTM0.09M
  • Revenue Per Share TTM0.008
  • Gross Profit TTM -0.32795M
  • Diluted EPS TTM-3.22

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -6.26873M -12.41352M -8.54908M -7.01504M -3.56780M
Minority interest 0.70M 0.47M - - -
Net income -5.57301M -11.94530M -8.54908M -7.01504M -2.89722M
Selling general administrative 3.06M 6.08M 4.49M 1.97M 1.25M
Selling and marketing expenses 0.07M 0.72M 0.51M - -
Gross profit -0.06144M 0.60M 0.44M 0.44M 0.86M
Reconciled depreciation 0.55M 0.59M 0.47M 0.28M -
Ebit -5.92556M -12.35967M -8.50645M -7.00270M -4.23838M
Ebitda -5.38033M -11.77113M -8.03220M -6.72765M -4.23838M
Depreciation and amortization 0.55M 0.59M 0.47M 0.28M -
Non operating income net other - - - - -
Operating income -7.16418M -13.20630M -9.37993M -7.00270M -4.23838M
Other operating expenses 6.49M 13.91M 9.17M 7.94M 4.24M
Interest expense 0.08M 0.05M 0.04M 0.01M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.08M 0.01M 0.00072M 0.12M 0.19M
Net interest income -0.07653M -0.04325M -0.04190M -0.01234M 0.09M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.72M 0.86M 1.30M 0.94M -0.67058M
Total revenue 0.30M 1.54M 0.66M 0.66M 0.86M
Total operating expenses 7.20M 14.25M 10.20M 7.94M 4.24M
Cost of revenue 0.36M 0.94M 0.23M 0.23M -
Total other income expense net 1.07M 1.28M 1.25M 0.93M 0.67M
Discontinued operations - - - - -
Net income from continuing ops -6.26873M -12.41352M -8.54908M -7.01504M -3.56780M
Net income applicable to common shares -5.57301M -11.94530M -8.54908M -7.01504M -3.56780M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 5.18M 33.89M 37.70M 39.37M 35.79M
Intangible assets - 0.81M 0.97M 1.12M 1.28M
Earning assets - - - - -
Other current assets 0.11M 0.11M 0.27M 0.21M 0.14M
Total liab 9.36M 2.18M 2.01M 1.54M 1.24M
Total stockholder equity -4.51492M 31.80M 35.20M 37.83M 34.55M
Deferred long term liab - - - - -
Other current liab - 0.14M 0.12M 0.09M 0.05M
Common stock 45.52M 45.52M 43.75M 36.65M 26.08M
Capital stock - 45.52M 43.75M 36.65M 26.08M
Retained earnings -81.33617M -44.76727M -39.19426M -27.24895M -18.69988M
Other liab - - - - -
Good will - 30.75M 30.75M 30.75M 30.75M
Other assets - 0.04M 0.06M 0.10M 0.11M
Cash 0.59M 0.15M 2.75M 4.97M 1.70M
Cash and equivalents - - - - -
Total current liabilities 7.09M 1.88M 1.63M 1.08M 0.67M
Current deferred revenue - -0.14253M -0.11671M -0.09053M -
Net debt 3.25M 0.29M -2.24550M -4.42004M -1.06472M
Short term debt 3.69M 0.14M 0.12M 0.09M 0.06M
Short long term debt - - - - -
Short long term debt total 3.84M 0.44M 0.50M 0.55M 0.63M
Other stockholder equity - -0.57018M 30.65M 28.43M 27.17M
Property plant equipment - 0.52M 0.85M 1.24M 1.58M
Total current assets 4.26M 1.77M 5.08M 6.09M 1.83M
Long term investments - 0.04M 0.06M 0.17M 0.35M
Net tangible assets - 0.24M 3.49M 5.96M 2.52M
Short term investments - - - -0.09985M -0.10822M
Net receivables 2.31M -0.00109M 0.26M 0.06M 0.06M
Long term debt - - - - -
Inventory 1.25M 1.53M 1.96M 0.87M -0.06414M
Accounts payable 3.41M 1.74M 1.51M 0.98M 0.56M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 31.31M 31.05M 30.65M 28.43M 27.17M
Additional paid in capital - - - - -
Common stock total equity - - - - 26.08M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.65M -32.07635M -32.56124M -33.17553M -33.84767M
Deferred long term asset charges - - - - -
Non current assets total 0.92M 32.12M 32.63M 33.28M 33.96M
Capital lease obligations - 0.44M 0.50M 0.55M 0.63M
Long term debt total - 0.30M 0.38M 0.46M 0.57M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 2.83M -0.20778M 1.38M 1.11M 0.73M
Change to liabilities 0.23M 0.53M 0.43M -0.05011M 0.30M
Total cashflows from investing activities 2.83M -0.20778M 1.38M 1.11M 0.73M
Net borrowings - - - - -
Total cash from financing activities 1.77M 7.10M 10.53M 4.50M 4.50M
Change to operating activities - - - - -
Net income -5.57301M -11.94530M -8.54908M -7.01504M -3.56780M
Change in cash -2.60020M -2.22471M 3.27M -1.37609M -2.61260M
Begin period cash flow 2.75M 4.97M 1.70M 3.07M 5.69M
End period cash flow 0.15M 2.75M 4.97M 1.70M 3.07M
Total cash from operating activities -7.24908M -9.42722M -8.61658M -6.93628M -7.79786M
Issuance of capital stock 1.77M 7.10M 10.62M 4.79M -
Depreciation 0.55M 0.59M 0.47M 0.28M 0.28M
Other cashflows from investing activities 2.83M -0.20778M 1.38M 0.93M 0.76M
Dividends paid - - - - -
Change to inventory 0.36M -1.08956M -0.86759M -0.86759M -0.86759M
Change to account receivables 0.28M -0.12098M -0.11590M -0.08425M 0.04M
Sale purchase of stock 1.77M 7.10M -0.08800M -0.28670M -0.28670M
Other cashflows from financing activities 2.83M -0.20778M 1.38M 1.11M 0.73M
Change to netincome -3.08462M 2.62M 0.02M -0.06192M -0.11907M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.02M 0.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.63M -1.21054M -0.98349M -0.08425M -2.08148M
Stock based compensation 0.40M 2.69M 1.30M 0.54M -
Other non cash items -2.22130M 1.93M -0.54176M -0.19628M 3.57M
Free cash flow -7.24908M -9.42722M -8.61658M -6.95224M -7.82608M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ZLD
Zelira Therapeutics Ltd		 0.01 1.64% 0.62 - - 71.70 0.33 128.18 -1.0946
CSL
CSL Ltd		 -3.45 1.22% 278.79 32.86 33.00 9.11 5.02 6.65 20.64
TLX
Telix Pharmaceuticals Ltd		 -0.07 0.27% 25.67 161.73 75.19 12.58 19.98 12.52 109.28
MSB
Mesoblast Ltd		 1.07 54.04% 3.05 - 454.55 312.43 2.49 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.79% 12.54 13.51 35.21 8.91 5.13 6.48 8.45

Reports Covered

Stock Research & News

View All

Profile

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Zelira Therapeutics Ltd

101 St Georges Terrace, Perth, WA, Australia, 6000

Key Executives

Name Title Year Born
Mr. Osagie O. Imasogie Esq. Founder & Chairman 1962
Dr. Oludare Odumosu MD, Global CEO & Director NA
Mr. Timothy Ryan Slate Non-Exec. Director & Company Sec. NA
Mr. Rahul Ganesan VP of Fin. & Accounting NA
Mr. Greg Blake VP of Global and Head of Commercial & Partnering NA
Dr. Patty Washer Clinical Trial Consultant NA
Mr. Greg Blake Executive Director NA
Mr. Timothy Ryan Slate Company Secretary & Non-Executive Director NA
Mr. Rahul Ganesan Vice President of Finance & Accounting NA
Mr. Greg Blake Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.